The pathopharmacology of malignant hyperpyrexia.
D000263:Adenylate Kinase / Q000172:deficiency; D000768:Anesthesia, General / Q000009:adverse effects; D000818:Animals; D001792:Blood Platelets / Q000503:physiopathology; D002118:Calcium / Q000378:metabolism / Q000502:physiology; D002395:Catecholamines / Q000494:pharmacology; D002415:Cats; D003620:Dantrolene / Q000494:pharmacology; D004285:Dogs; D005334:Fever / Q000209:etiology; D005947:Glucose / Q000378:metabolism; D006801:Humans; D008305:Malignant Hyperthermia / Q000473:pathology / Q000503:physiopathology* / Q000662:veterinary; D008928:Mitochondria / Q000378:metabolism; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000473:pathology; D009135:Muscular Diseases / Q000150:complications / Q000503:physiopathology; D010179:Pancreas / Q000503:physiopathology; D011343:Procaine / Q000494:pharmacology; D013552:Swine; D013553:Swine Diseases / Q000378:metabolism / Q000503:physiopathology; D013696:Temperature
D002395:Catecholamines; D011343:Procaine; D000263:Adenylate Kinase; D003620:Dantrolene; D005947:Glucose; D002118:Calcium